Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches - PubMed
- ️Fri Jan 01 2021
Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches
Paul Dowling et al. Proteomes. 2021.
Abstract
Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells which are incapable of differentiating into mature leukocytes. AML risk stratification is based on genetic background, which also serves as a means to identify the optimal treatment of individual patients. However, constant refinements are needed, and the inclusion of significant measurements, based on the various omics approaches that are currently available to researchers/clinicians, have the potential to increase overall accuracy with respect to patient management. Using both nontargeted (label-free mass spectrometry) and targeted (multiplex immunoassays) proteomics, a range of proteins were found to be significantly changed in AML patients with different genetic backgrounds. The inclusion of validated proteomic biomarker panels could be an important factor in the prognostic classification of AML patients. The ability to measure both cellular and secreted analytes, at diagnosis and during the course of treatment, has advantages in identifying transforming biological mechanisms in patients, assisting important clinical management decisions.
Keywords: acute myeloid leukemia; biomarkers; immunoassay; mass spectrometry; proteomics.
Conflict of interest statement
C.A.H. has received research funding from Celgene/BMS, Kronos Bio, Novartis, Oncopeptides, Orion Pharma and the IMI2 projects HARMONY and HARMONY PLUS unrelated to this work.
Figures

Pathway analysis (cells) comparing significant proteins found to be elevated in Group 1 (Gr1—favourable) and Group 3 (Gr3—adverse) when compared.

Pathway analysis (cells) comparing significant proteins found to be elevated in Group 1 (Gr1—favorable) and Group 2 (Gr2—intermediate) when compared.

Pathway analysis (cells) comparing significant proteins found to be elevated in Group 2 (Gr2—intermediate) and Group 3 (Gr3—adverse) when compared.

Box and Whisker plots for IL-17A, IL-1RA, SDF-1α1β and IL-1α based on results from serum biomarker analysis using targeted multiplexed immunoassays.
Similar articles
-
Xu Y, Zhuo J, Duan Y, Shi B, Chen X, Zhang X, Xiao L, Lou J, Huang R, Zhang Q, Du X, Li M, Wang D, Shi D. Xu Y, et al. Int J Clin Exp Pathol. 2014 Aug 15;7(9):5569-81. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25337199 Free PMC article.
-
Proteogenomic profiling of acute myeloid leukemia to identify therapeutic targets.
Murray HC, Sillar J, Chambers M, Verrills NM. Murray HC, et al. Expert Rev Proteomics. 2024 Nov 22:1-14. doi: 10.1080/14789450.2024.2431272. Online ahead of print. Expert Rev Proteomics. 2024. PMID: 39576246
-
Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia.
Zhang Z, Huang J, Zhang Z, Shen H, Tang X, Wu D, Bao X, Xu G, Chen S. Zhang Z, et al. Biomark Res. 2024 Jun 10;12(1):60. doi: 10.1186/s40364-024-00600-1. Biomark Res. 2024. PMID: 38858750 Free PMC article. Review.
-
Therapy of acute myeloid leukemia: towards a patient-oriented, risk-adapted approach.
Mandelli F, Petti MC, Lo Coco F. Mandelli F, et al. Haematologica. 1998 Nov;83(11):1015-23. Haematologica. 1998. PMID: 9864924 Review.
-
Acute Myeloid Leukemia: Diagnosis and Management Based on Current Molecular Genetics Approach.
Suguna E, Farhana R, Kanimozhi E, Kumar PS, Kumaramanickavel G, Kumar CS. Suguna E, et al. Cardiovasc Hematol Disord Drug Targets. 2018;18(3):199-207. doi: 10.2174/1871529X18666180515130136. Cardiovasc Hematol Disord Drug Targets. 2018. PMID: 29766829 Review.
Cited by
-
Mitochondria and Acute Leukemia: A Clinician's Perspective.
Iyer P, Jasdanwala SS, Bhatia K, Bhatt S. Iyer P, et al. Int J Mol Sci. 2024 Sep 7;25(17):9704. doi: 10.3390/ijms25179704. Int J Mol Sci. 2024. PMID: 39273651 Free PMC article. Review.
-
Role of Biomarkers in the Management of Acute Myeloid Leukemia.
Small S, Oh TS, Platanias LC. Small S, et al. Int J Mol Sci. 2022 Nov 22;23(23):14543. doi: 10.3390/ijms232314543. Int J Mol Sci. 2022. PMID: 36498870 Free PMC article. Review.
-
Stratmann S, Vesterlund M, Umer HM, Eshtad S, Skaftason A, Herlin MK, Sundström C, Eriksson A, Höglund M, Palle J, Abrahamsson J, Jahnukainen K, Munthe-Kaas MC, Zeller B, Tamm KP, Lindskog C, Cavelier L, Lehtiö J, Holmfeldt L. Stratmann S, et al. Leukemia. 2023 Mar;37(3):550-559. doi: 10.1038/s41375-022-01796-7. Epub 2022 Dec 26. Leukemia. 2023. PMID: 36572751 Free PMC article.
-
Matou-Nasri S, Najdi M, AlSaud NA, Alhaidan Y, Al-Eidi H, Alatar G, AlWadaani D, Trivilegio T, AlSubait A, AlTuwaijri A, Abudawood M, Almuzzaini B. Matou-Nasri S, et al. PLoS One. 2022 May 5;17(5):e0267855. doi: 10.1371/journal.pone.0267855. eCollection 2022. PLoS One. 2022. PMID: 35511922 Free PMC article.
-
Dickkopf-3: An Update on a Potential Regulator of the Tumor Microenvironment.
Al Shareef Z, Ershaid MNA, Mudhafar R, Soliman SSM, Kypta RM. Al Shareef Z, et al. Cancers (Basel). 2022 Nov 25;14(23):5822. doi: 10.3390/cancers14235822. Cancers (Basel). 2022. PMID: 36497305 Free PMC article. Review.
References
-
- Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann. Intern. Med. 1985;103:620–625. doi: 10.7326/0003-4819-103-4-620. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials